Routine
Notice
Added
Triacetyl-3-hydroxyphenyladenosine patent for fatty liver
Detected
April 1st, 2026
Summary
Triacetyl-3-hydroxyphenyladenosine patent for fatty liver
Source document (simplified)
TRIACETYL-3-HYDROXYPHENYLADENOSINE AND APPLICATION IN PREPARING PHARMACEUTICAL DRUG FOR PREVENTING OR TREATING NON-ALCOHOLIC FATTY LIVER DISEASE
Publication EP3398604A1 Kind: A1 Mar 25, 2026
Applicants
Beijing Gushen Life Health Technology Co., Ltd., Institute of Materia Medica, Chinese Academy
of Medical Sciences
Inventors
ZHU, Haibo, SHI, Huijie
IPC Classifications
A61K 31/7076 20060101AFI20190513BHEP A61P 1/16 20060101ALI20190513BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Source
Analysis generated by AI. Source diff and links are from the original.
Classification
Browse Categories
Agriculture & Food Safety
63
AI Regulation
3
Banking & Finance
266
Consumer Protection
44
Courts & Legal
361
Data Privacy & Cybersecurity
74
Defense & National Security
52
Education
20
Energy
101
Environment
85
Environmental Permits
1
Environmental Regulation
13
Government & Legislation
278
Healthcare
136
Housing
16
Immigration
9
Insurance
58
Labor & Employment
113
Legislative
1
Pharma & Drug Safety
104
Public Health
3
Securities & Markets
104
Securities Regulation
15
Tax
66
Telecom & Technology
47
Trade & Sanctions
124
Transportation
57
Get Pharma & Drug Safety alerts
Weekly digest. AI-summarized, no noise.
Free. Unsubscribe anytime.
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Therapeutics (A61P) publishes new changes.